MARKET

SPPI

SPPI

Spectrum Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7098
+0.0002
+0.03%
After Hours: 0.7200 +0.0102 +1.44% 19:42 05/25 EDT
OPEN
0.7042
PREV CLOSE
0.7096
HIGH
0.7299
LOW
0.6922
VOLUME
953.09K
TURNOVER
0
52 WEEK HIGH
4.540
52 WEEK LOW
0.6000
MARKET CAP
127.83M
P/E (TTM)
-0.8164
1D
5D
1M
3M
1Y
5Y
Spectrum Pharmaceuticals to Participate in H.C. Wainwright Global Investment Conference
HENDERSON, Nev., May 17, 2022--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the upcoming H.C. Wainwright Global Investment Confe...
Business Wire · 05/17 11:00
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI): Is Breakeven Near?
We feel now is a pretty good time to analyse Spectrum Pharmaceuticals, Inc.'s ( NASDAQ:SPPI ) business as it appears...
Simply Wall St. · 05/14 13:18
BRIEF-Spectrum Pharmaceuticals Reports Q1 2022 Results
reuters.com · 05/12 20:58
Spectrum Pharmaceuticals: Q1 Earnings Insights
Spectrum Pharmaceuticals (NASDAQ:SPPI) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Benzinga · 05/12 20:50
Spectrum Pharmaceuticals Non-GAAP EPS of -$0.06
Spectrum Pharmaceuticals press release (NASDAQ:SPPI): Q1 Non-GAAP EPS of -$0.06. In January, the company received a $20 million strategic equity investment from Hanmi Pharmaceutical. Together with this strategic investment, Spectrum
Seekingalpha · 05/12 20:02
Spectrum Pharmaceuticals Q1 EPS $(0.06) Beats $(0.19) Estimate
Spectrum Pharmaceuticals (NASDAQ:SPPI) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.19) by 68.42 percent. This is a 70 percent increase over losses of $(0.20) per share
Benzinga · 05/12 20:01
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/12 12:42
Spectrum Pharmaceuticals's Earnings Outlook
Spectrum Pharmaceuticals (NASDAQ:SPPI) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that Spectrum Pharmaceuticals will report an earnings per shar...
Benzinga · 05/11 17:04
More
No Data
Learn about the latest financial forecast of SPPI. Analyze the recent business situations of Spectrum Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

20.00%Strong Buy
60.00%Buy
20.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SPPI stock price target is 5.60 with a high estimate of 10.00 and a low estimate of 3.000.
High10.00
Average5.60
Low3.000
Current 0.7098
EPS
Actual
Estimate
-0.26-0.19-0.13-0.06
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 194
Institutional Holdings: 77.99M
% Owned: 43.31%
Shares Outstanding: 180.09M
TypeInstitutionsShares
Increased
17
16.97M
New
15
826.17K
Decreased
45
37.68M
Sold Out
54
7.01M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.55%
Pharmaceuticals & Medical Research
+0.02%
Key Executives
Non-Executive Chairman/Independent Director
William Ashton
President/Chief Executive Officer/Chief Financial Officer/Director
Thomas Riga
Executive Vice President/Secretary
Keith Mcgahan
Executive Vice President
Francois Lebel
Director
Juhyun Lim
Independent Director
Brittany Bradrick
Independent Director
Nora Brennan
Independent Director
Seth Fischer
Independent Director
Jeffrey Vacirca
Independent Director
Dolatrai Vyas
Independent Director
Bernice Welles
No Data
No Data
About SPPI
Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's product portfolio consists of in-development drug products for the treatment of cancer patients. Its pipeline products include ROLONTIS, Poziotinib and Anti-CD20-IFNa. ROLONTIS (eflapegrastim injection), is a long-acting granulocyte colony-stimulating factor (G-CSF) for chemotherapy-induced neutropenia. Poziotinib, is a pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (EGFR) family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations. Anti-CD20-IFNa, is an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for treating relapsed or refractory non-Hodgkin's lymphoma (NHL) patients.

Webull offers kinds of Spectrum Pharmaceuticals, Inc. stock information, including NASDAQ:SPPI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SPPI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SPPI stock methods without spending real money on the virtual paper trading platform.